ANRO (Alto Neuroscience) Change In Payables And Accrued Expense : $3.59 Mil (TTM As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Alto Neuroscience Change In Payables And Accrued Expense?

Alto Neuroscience's Change In Payables And Accrued Expense for the quarter that ended in Sep. 2024 was $2.04 Mil. It means Alto Neuroscience's Accounts Payable & Accrued Expense increased by $2.04 Mil from Jun. 2024 to Sep. 2024 .

Alto Neuroscience's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was $-0.99 Mil. It means Alto Neuroscience's Accounts Payable & Accrued Expense declined by $0.99 Mil from Dec. 2022 to Dec. 2023 .

Alto Neuroscience Change In Payables And Accrued Expense Historical Data

The historical data trend for Alto Neuroscience's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alto Neuroscience Change In Payables And Accrued Expense Chart

Alto Neuroscience Annual Data

Trend

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

1.10

3.48

-0.99

Alto Neuroscience Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial					0.62	-1.28	1.53	1.31	2.04

Alto Neuroscience Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.59 Mil.

Alto Neuroscience Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Alto Neuroscience's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Alto Neuroscience Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alto Neuroscience Inc (NYSE:ANRO) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

369 South San Antonio Road, Los Altos, CA, USA, 94022

Website

https://www.altoneuroscience.com

Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.